会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明申请
    • PROSTATIC STENT WITH LOCALIZED TISSUE ENGAGING ANCHORING MEANS
    • 具有局部组织参与锚固手段的前置支架
    • WO0202032A3
    • 2002-08-29
    • PCT/US0115585
    • 2001-05-15
    • ARGOMED LTDLAZAROVITZ JACOBCIOANTA IULIANKLEIN RICHARD BARRY
    • LAZAROVITZ JACOBCIOANTA IULIANKLEIN RICHARD BARRY
    • A61M1/00A61B17/00A61B17/22A61B18/14A61F2/00A61F2/84A61F7/12A61M25/00A61M25/10A61B17/12A61B18/04A61M25/04
    • A61M25/1011A61B18/1492A61B2017/00274A61B2017/22069A61B2018/00547A61F2/0027
    • A prostatic stent is configured as a unitary body which is adapted to reside above the sphincter when in position in the subject includes an elongated tube which extends through the sphincter and outside the body of the subject. The stent is configured to allow natural operation of the sphincter when in position in the subject. The unitary body stent includes a lower inflatable portion which expands to contact tissue and help hold the stent in a desired location during a chronic use period of about 2-14 days. The stent can also include an upper and/or intermediate inflatable portions. A method of inhibiting the obstruction or closure of the prostatic urethral opening includes positioning the stent in the subject such that the unitary body of the stent is in the prostate and resides above the sphincter. A method treating BPH includes thermally ablating localized tissue in the prostate and inserting a post-treatment catheter into the prostate (preferably after an initial healing period) to allow the treated tissue to contour therearound and to maintain the urinary passage open. The stent is configured as a unitary body stent adapted to reside above the sphincter of the subject and to allow substantially normal operation of the sphincter. The stent can include a lower inflatable portion which engages, when expanded, with tissue below the localized treatment region about the membranous urethra (between the sphincter and the verumontanum). The post-treatment catheter is configured to reside in the subject for a period of about 2-14 days after delivery of the thermal ablation treatment or therapy.
    • 前列腺支架被构造为整体,其适于驻留在括约肌上方,当被检体中的适当位置包括延伸穿过括约肌并在受试者体外时的细长管。 支架构造成允许括约肌在受试者中处于适当位置时自然操作。 整体式支架包括下部可充气部分,其在约2-14天的慢性使用期间膨胀以接触组织并帮助将支架保持在期望的位置。 支架还可以包括上部和/或中间的可充气部分。 抑制前列腺尿道开口的阻塞或闭合的方法包括将支架定位在受试者中,使得支架的整体位于前列腺内且位于括约肌上方。 治疗BPH的方法包括热消融前列腺中的局部组织并将后处理导管插入前列腺中(优选在初始愈合期后),以允许经处理的组织在其周围轮廓并保持尿路畅通。 支架被配置为适于驻留在受试者的括约肌上方并且允许括约肌基本上正常操作的整体体支架。 支架可以包括下部可充气部分,其在扩张时与局部治疗区域周围的组织接合围绕膜性尿道(在括约肌和肋骨之间)。 后处理导管构造成在传递热消融治疗或治疗后约2-14天的时间内居住在受试者中。